AstraZeneca Plans to Advance the Combination of Neutralizing Antibody for COVID-19 into Clinical in Next Two Months

 AstraZeneca Plans to Advance the Combination of Neutralizing Antibody for COVID-19 into Clinical in Next Two Months

AstraZeneca Reports Results of Imfinzi + Tremelimumab in P-III CASPIAN Study as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

Shots:

  • AstraZeneca has licensed Vanderbilt University’s coronavirus-neutralizing Abs & plans to advance a pair of these mAbs into clinical development as a combination therapy for COVID-19. The agreement follows AstraZeneca and Vanderbilt collaboration in Apr’20
  • AstraZeneca has evaluated the ability of 1,500+ mAbs to bind to the SARS-CoV-2 virus and inhibit its capacity to infect healthy cells in a laboratory setting. Based on pre-clinical results, the company has signed an exclusive license to six Abs currently in Vanderbilt’s portfolio targeting COVID-19. 2 out of 6 mAbs will progress into clinical evaluation as a combination approach within the next 2mos.
  • Additionally, AstraZeneca has signed an interagency agreement with DARPA and BARDA to support the development of mAb against COVID-19 including P-I clinical study and the manufacturing of the investigational product for testing in P-I

Click here to read full press release/ article | Ref: AstraZeneca | Image: AstraZeneca

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post